
The zzso of multiple potential targets in cancer cells and the development of multiple zzso zzso agents provide unique challenges in clinical trial zzso Many of these agents are predicted to have zzso as opposed to zzso effects and thus the traditional surrogate zzso of zzso tumor shrinkage may be zzso The ethical and safety issues of obtaining multiple tumor zzso further complicate the assessment of appropriate target zzso in zzso We discuss specific issues that need to be addressed during zzso phase I, II, and III testing of these zzso We propose clinical trial designs, including a zzso zzso design during phase II zzso that may be particularly useful for zzso zzso zzso 

